Lilly Scoops Up Protomer Technologies In Over $1B Deal
- Eli Lilly And Co LLY 0.06% has acquired privately-held biotech firm Protomer Technologies in a deal valued at more than $1 billion.
- Lilly previously led an equity investment in Protomer alongside the JDRF T1D Fund, providing Lilly with 14% ownership.
- Protomer offers a peptide- and protein engineering platform to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
- Aquilo Partners LP is acting as a financial advisor, and Morrison & Foerster LLP a legal advisor to Protomer.
- Kirkland & Ellis LLP is serving as Lilly's legal counsel.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.